GH Research GHRS
NASDAQ GHRS
$28.23 +0.31 (+1.11%)
As of: Sep 4, 2026 · 3:59 PM EDT

GH Research (GHRS) Other Accumulated Expenses (2021 - 2026)

GH Research (GHRS) posted quarterly Other Accumulated Expenses of $4.2 million for Q4 2025, down 14.42% year-over-year from $5.0 million in Q4 2024, and down 31.65% quarter-over-quarter from $6.2 million in Q3 2025.

Analysis

GH Research (GHRS) Other Accumulated Expenses (2021 - 2026) Analysis & Trends

GH Research's Other Accumulated Expenses history runs 5 years deep, the most recent figure standing at $4.2 million for Q4 2025.

  • In Q4 2025, Other Accumulated Expenses fell 14.42% year-over-year to $4.2 million; the TTM figure through Dec 2025 stood at $4.2 million (down 14.42% YoY), while the FY2025 annual figure was $4.2 million, down 14.42% from the prior year.
  • Other Accumulated Expenses for Q4 2025 stood at $4.2 million, down from $6.2 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $6.6 million in Q3 2024, with the low at $819000.0 in Q3 2021.
  • The 5-year median for Other Accumulated Expenses is $3.4 million (2023), against an average of $3.7 million.
  • The sharpest annual moves came in 2023 and 2025: Other Accumulated Expenses surged 143.37% in 2023, then retreated 14.42% in 2025.
  • GH Research's Other Accumulated Expenses stood at $3.0 million in 2021, then declined by 10.22% to $2.7 million in 2022, then gained by 7.09% to $2.9 million in 2023, then soared by 72.84% to $5.0 million in 2024, then dropped by 14.42% to $4.2 million in 2025.
  • Business Quant data shows GHRS's Other Accumulated Expenses at $4.2 million in Q4 2025, $6.2 million in Q3 2025, and $6.2 million in Q2 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 GH Research 1.72 Bn 1.36 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.57 Mn
Mar 31, 2026 6.25 Mn
Dec 31, 2025 4.24 Mn
Sep 30, 2025 6.21 Mn
Jun 30, 2025 6.16 Mn
Mar 31, 2025 4.81 Mn
Dec 31, 2024 4.96 Mn
Sep 30, 2024 6.57 Mn
Jun 30, 2024 4.97 Mn
Mar 31, 2024 3.39 Mn
Dec 31, 2023 2.87 Mn
Sep 30, 2023 3.17 Mn
Jun 30, 2023 3.38 Mn
Mar 31, 2023 3.38 Mn
Dec 31, 2022 2.68 Mn
Sep 30, 2022 1.64 Mn
Jun 30, 2022 1.39 Mn
Mar 31, 2022 2.52 Mn
Dec 31, 2021 2.98 Mn
Sep 30, 2021 819,000.00